Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) supports researchers pursuing scientific and clinical studies to improve diagnosis, clarify disease mechanisms, or advance treatment.
Funder: National Organization for Rare Disorders
Due Dates: January 19, 2027, 11:59 pm PT (Initial application / Letter of intent) | March 2027 (Full proposal invitations) | June 2027 (Award announcements)
Funding Amounts: One grant up to US$50,000; project term of one or two years
Summary: Supports scientific and clinical research to improve diagnosis, understanding, or treatment of alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV).
Key Information: PI salary, overhead, and indirect costs cannot be funded.
The National Organization for Rare Disorders (NORD), with donations from the ACDMPV community, supports scientific and clinical studies of alveolar capillary dysplasia with misalignment of pulmonary veins. ACDMPV is a rare, lethal developmental lung disorder affecting newborns, most often associated with mutations or deletions involving the FOXF1 gene or its distant regulatory genomic region.
Through its Rare Disease Research Grants Program, NORD funds qualified researchers to initiate studies or clinical trials that improve diagnosis, clarify underlying disease mechanisms, or advance therapy. The award is intended to generate results that could attract subsequent support from the NIH, FDA, other funding agencies, or a corporate sponsor. Ideally, the research will contribute to the development of a new or better therapy.